retatrutide phase 3 trials FDA Approval Status 2026: Everything We Know So Far New Retatrutide Phase 3 Trial

For patients first prescribed an AOM in December 2024, 50.5% filled a GLP-1 RA within 60 days

122 Interestingly, GLP-1/estrogen demonstrates a promising role in improving ovarian cyclicity in milder PCOS phenotypes with preserved ovulatory function, effectively normalizing cycle irregularities and enhancing reproductive hormonal balance, while, at lower doses, it outperformed other multi-agonists by reducing body weight (by 10%), fat mass (by 50%), and improving glucose metabolism and insulin sensitivity in PCOS models, without causing significant changes in ovarian or uterine parameters

For a full list of side effects, please review the Mayo Clinics Semaglutide and Tirzepatide resources

Delve into the concept of mindful eating and discover its benefits, including improved glucose control and healthier food choices